A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 microg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women.

Trial Profile

A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 microg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Calcitonin (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Unigene Laboratories
  • Most Recent Events

    • 11 Mar 2013 Positive results from this trial were reported at the 2012 Annual Meeting of the American Society of Bone and Mineral Research (ASBMR), according to a Unigene Laboratories media release.
    • 22 Mar 2009 Actual end date (1-Jan-2009) added as reported by ClinicalTrials.gov.
    • 03 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by a Unigene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top